U.S. Bioethics Panel to Review Clinical Trials Around the World
By Jocelyn Kaiser,
ScienceInsider
| 03. 01. 2011
Prompted by concerns about an unethical U.S.-sponsored study in the 1940s, bioethics advisers to President Barack Obama formed an international panel today that will examine whether current rules adequately protect volunteers in global clinical trials.
A historian at Wellesley College shocked the nation last October with the revelation that, from 1946 to 1948, a U.S. Public Health Service researcher deliberately exposed Guatemalan prisoners, soldiers, and others to syphilis and gonorrhea. The experiments drew comparisons with Tuskegee, the notorious 40-year study in Alabama begun in 1932 in which U.S. researchers allowed hundreds of African-American men with syphilis to go untreated.
In response, President Obama asked his Presidential Commission for the Study of Bioethical Issues to examine whether "current rules for research participants protect people from harm or unethical treatment, domestically as well as internationally." Obama also asked the Institute of Medicine (IOM) to investigate the Guatemala study. But that fact-finding job also fell to the bioethics commission after IOM realized that five of its members had been involved in the study. The commission is chaired by University of Pennsylvania President Amy...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...